Evidence of the efficacy and safety of house dust mite subcutaneous immunotherapy in elderly allergic rhinitis patients: a randomized, double-blind placebo-controlled trial

Table 2 Efficacy of AIT during therapy compared to placebo

Patients	AAdSS ± SD
Patients	Baseline	After 2 years AIT	Difference in the adjusted means^a
AIT active; n = 30	4.27 ± 1.58	1.82 ± 0.71	− 3.39
ITT population	4.27 ± 1.58	1.82 ± 0.71	− 3.39
AIT placebo; n = 28	4.26 ± 1.6	3.97 ± 0.96	− 0.82
ITT population	4.26 ± 1.6	3.97 ± 0.96	− 0.82
AIT active; n = 29	4.34 ± 1.71	1.93 ± 0.64	− 3.51
modified ITT population	4.34 ± 1.71	1.93 ± 0.64	− 3.51
AIT placebo; n = 26	4.46 ± 1.69	3.92 ± 1.11	− 0.87
modified ITT population	4.46 ± 1.69	3.92 ± 1.11	− 0.87

ISSN: 2045-7022